Marksans Pharma’s UK Subsidiary Wins MHRA Approval for Mefenamic Acid Tablets

Marksans Pharma’s UK subsidiary, Relonchem Limited, has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Mefenamic Acid tablets in 250mg and 500mg strengths. The approval strengthens the company’s UK product lineup and reinforces its presence in one of its key international markets.

Portfolio Expansion in a Key International Market

The addition of Mefenamic Acid, a widely used NSAID for menstrual pain and other mild to moderate pain conditions, broadens Relonchem’s therapeutic offerings in the UK and supports Marksans Pharma’s ambition to expand its global product footprint.

Strategic Boost to UK Market Positioning

With this approval, Marksans Pharma enhances its competitive standing in the UK pharmaceutical sector. Although immediate financial impact has not been disclosed, the move aligns with the company’s long-term strategy of strengthening international operations and diversifying its regulated-market portfolio.